Please assess the completion status of the following clinical trial:

Trial Title: Clofarabine Bone Marrow Cytoreduction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.~* Adequate hepatobiliary function as indicated by the following laboratory values:~  * SGOT/SGPT \<=2.5 x upper limit of normal~ * Alkaline phosphatase \<=2.5 x upper limit of normal~ * Serum bilirubin \< 1.5 mg/dl~ * Adequate renal function as indicated by the following laboratory values:~ * Creatinine Clearance \>50 ml/min~* Age \>/=18 years~* Zebroid performance status \</= 2 (See Appendix A)~* Life expectancy is not severely limited by concomitant illness (i.e. \< 3months life expectancy from non-leukemic conditions).~* No evidence of chronic active hepatitis or cirrhosis.~* HIV-negative~* Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.~* Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.~Exclusion Criteria:~* Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.~* Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea. The patient must have recovered from all acute non-hematologic toxicities from any previous .~* Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.~* Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).~* Pregnant or lactating patients.~* Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clofarabine (Type: EXPERIMENTAL): Clofarabine 30 mg/m2/day IV infusion over one hour for 5 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).